What’s Happening
Chatter
- Transferring from US to LatAM
- In awe every single time
- Switching from pharma to medical device observational CRA – differences?
- Coding Programs for Molecular Biologists
- Laboratory day!
- looking for licensed chemist
- How do R&D departments in the same company but different cities/countries collaborate?
- Abbott interview for software complaint Investigation Enginner
- Dropped from life-saving Phase 3 trial due to site scheduling error — desperate for compassionate use or Right to Try guidance
- vent about regretting leaving my toxic lab
- Dropped from life-saving Phase 3 trial due to site scheduling error — desperate for compassionate use or Right to Try guidance
- Working at Myriad Genetics
- PCR Gel Help
- Physical assault at work
- is emerson research instituite legit?
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…